Corpus Intelligence IC Memo — CHARLES A DEAN MEMORIAL HOSPITAL 2026-04-26 06:17 UTC
IC Memo — CHARLES A DEAN MEMORIAL HOSPITAL
Investment Committee Memorandum | ME | 25 beds | Grade D | EBITDA uplift $1.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CHARLES A DEAN MEMORIAL HOSPITAL

CCN 201301 | PISCATAQUIS, ME | 25 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

CHARLES A DEAN MEMORIAL HOSPITAL is a 25-bed safety-net/medicaid heavy in PISCATAQUIS, ME with $20.3M in net patient revenue and a -6.5% operating margin. The hospital serves a payer mix of 9.3% Medicare, 56.6% Medicaid, and 34.1% commercial.

Thesis: Turnaround. Our ML models identify $1.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -6.5% to 0.8% (+736bps).

Net Revenue HCRIS$20.3M
Current EBITDA COMPUTED$-1.3M
Operating Margin COMPUTED-6.5%
Occupancy HCRIS50.6%
Revenue / Bed COMPUTED$812K
Net-to-Gross HCRIS74.1%
Distress Probability ML65.1%

2. Market Context & Competitive Position

38
ME Hospitals
-8.3%
State Median Margin
21
Comparable Hospitals

ME has 38 Medicare-certified hospitals with a median operating margin of -8.3%. The target's margin of -6.5% places it above the state median. Among 21 size-comparable peers (12-50 beds), the median margin is -5.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 21 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CHARLES A DEAN MEMORIAL HOSPIT (Target)ME25$20.3M-6.5%
REDINGTON-FAIRVIEW GENERAL HOSME25$135.4M-3.6%
THE AROOSTOOK MEDICAL CENTERME34$134.8M-23.5%
LINCOLNHEALTHME25$116.8M-0.9%
WALDO COUNTY GENERAL HOSPITALME25$115.4M-6.4%
FRANKLIN MEMORIAL HOSPITALME46$103.4M-17.3%
STEPHENS MEMORIAL HOSPITAL - CME25$100.5M4.2%
MAINE COAST MEMORIAL HOSPITALME45$98.0M-5.5%
MOUNT DESERT ISLAND HOSPITALME25$74.8M-10.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$426K+210bp18mo
Cost to Collect4.5%2.5%$406K+200bp12mo
Denial Rate Reduction12.0%6.5%$402K+198bp12mo
A/R Days Reduction5200.0%3800.0%$247K+122bp9mo
Clean Claim Rate88.0%96.0%$13K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$426K
Cost to Collect
$406K
Denial Rate Reduction
$402K
A/R Days Reduction
$247K
Clean Claim Rate
$13K
Total EBITDA Uplift$1.5M
Current EBITDA$-1.3M
+ RCM Uplift+$1.5M
Pro Forma EBITDA$171K
Current Margin-6.5%
Pro Forma Margin0.8%
WC Released (1x)$778K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.0M$6.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.0M$6.2M0.00x-100.0%
Bull Case9.0x11.0x$-1.8M$10.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.8M$10.8M0.00x-100.0%
Bear Case11.0x10.0x$-2.2M$-598K0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.2M$-1.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (56.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 65.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 21 hospitals with 12-50 beds
  • Same-state prioritization (n=22)
  • Comp margins: P25=-10.8% / P50=-5.5% / P75=1.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.